Which medications in the drug class Pulmonary, Tyrosine Kinase Inhibitors are used in the treatment of Interstitial (Nonidiopathic) Pulmonary Fibrosis?

Updated: Sep 15, 2020
  • Author: Eleanor M Summerhill, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Pulmonary, Tyrosine Kinase Inhibitors

Inhibition of various tyrosine kinases decreases the proliferative activities that lead to fibrosis.

Nintedanib (Ofev)

Nintedanib inhibits multiple tyrosine kinases and targets growth factors, which have been shown to be potentially involved in pulmonary fibrosis (eg, vascular endothelial growth factor receptor [VEGFR], fibroblast growth factor receptor [FGFR], platelet-derived growth factor receptor [PDGF]. It binds competitively to the adenosine triphosphate (ATP)-binding pocket of these receptors and blocks the intracellular signaling, which is crucial for the proliferation, migration, and transformation of fibroblasts, representing essential mechanisms of the idiopathic pulmonary fibrosis pathology.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!